Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $405.3333.

Several brokerages have recently issued reports on ALNY. UBS Group lifted their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Raymond James Financial began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price target on the stock. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th.

Alnylam Pharmaceuticals Trading Down 2.8%

Shares of Alnylam Pharmaceuticals stock opened at $454.38 on Monday. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The business’s 50 day moving average is $360.65 and its 200-day moving average is $296.70. The stock has a market cap of $59.56 billion, a P/E ratio of -183.96 and a beta of 0.25. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773,689 billion for the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The business’s revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,274 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the sale, the executive vice president directly owned 50,121 shares in the company, valued at approximately $22,718,345.67. The trade was a 4.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 6,979 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the transaction, the chief executive officer directly owned 56,221 shares in the company, valued at $25,483,292.67. This trade represents a 11.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,531 shares of company stock valued at $41,087,238. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after acquiring an additional 185,783 shares during the last quarter. Geode Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after acquiring an additional 75,936 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its stake in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.